Skip to main content
Livermore
Livermore
ZHEN

Suvretta Capital Management, LLC

SEC CIK
0001569064
Latest filing
Aug 14, 2026

The latest 13F from Suvretta Capital Management, LLC covers Q2 2026 (filed Aug 14, 2026): 95 long positions worth $4.76B. The top 10 holdings make up 44.6% of the portfolio, and the largest is Veradermics, Inc (MANE) at 10.8%. Livermore has 24 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
21
Est. +$447.2M
Added
25
Est. +$299.3M
Reduced
17
Est. −$246.8M
Sold out
14
Est. −$342.8M

Top 5 holdings

Share of this quarter's portfolio value

  1. MANEVeradermics, Inc
    10.8%$512.5MHistory
  2. ARQTArcutis Biotherapeutics, Inc.
    6.9%$326.1MHistory
  3. LEGNLegend Biotech Corp
    4.3%$204.2MHistory
  4. PVLAPalvella Therapeutics, Inc.
    3.6%$173.5MHistory
  5. AVBPArriVent BioPharma, Inc.
    3.3%$156.9MHistory

Share of portfolio

Top 5 holdings and the other 90 positions, by share of portfolio value

  1. MANE10.8%
  2. ARQT6.9%
  3. LEGN4.3%
  4. PVLA3.6%
  5. AVBP3.3%
  6. Other 90 positions71.1%

Biggest buys

New and added positions, by estimated amount bought

  1. AVLNAvalyn Pharma Inc.
    +$82.4MNewHistory
  2. HUTHut 8 Corp.
    +$77.3MNewHistory
  3. FTHFaeth Therapeutics, Inc.
    +$49.6MAddedHistory
  4. APHAmphenol Corp
    +$47.5MNewHistory
  5. SPOTSpotify Technology S.A.
    +$46.2MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. AVLNAvalyn Pharma Inc.
    +1.73 pp0.0% → 1.7%History
  2. HUTHut 8 Corp.
    +1.63 pp0.0% → 1.6%History
  3. FTHFaeth Therapeutics, Inc.
    +1.03 pp<0.1% → 1.1%History
  4. APHAmphenol Corp
    +1.00 pp0.0% → 1.0%History
  5. SPOTSpotify Technology S.A.
    +0.97 pp<0.1% → 1.0%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. APLSApellis Pharmaceuticals, Inc.
    −$141.5MSold outHistory
  2. KALVKalVista Pharmaceuticals, Inc.
    −$96.0MSold outHistory
  3. ERASErasca, Inc.
    −$55.6MSold outHistory
  4. PFGCPerformance Food Group Co
    −$41.6MReducedHistory
  5. USFDUS Foods Holding Corp.
    −$39.8MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. APLSApellis Pharmaceuticals, Inc.
    −3.84 pp3.8% → 0.0%History
  2. KALVKalVista Pharmaceuticals, Inc.
    −2.60 pp2.6% → 0.0%History
  3. ERASErasca, Inc.
    −1.51 pp1.5% → 0.0%History
  4. CMPXCompass Therapeutics, Inc.
    −1.40 pp2.1% → 0.6%History
  5. FULCFulcrum Therapeutics, Inc.
    −1.08 pp1.4% → 0.3%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$4.76B
+$1.07B (+29.0%) vs. prior quarter
Positions
95
+7 vs. prior quarter
Top 10 concentration
44.6%
Top 10 as share of value
Turnover
14.0%
Q2 2026, one quarter
Average holding period
8.5 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $6.73B (Q1 2021)

Q1 2021: $6.73BQ2 2021: $6.66BQ3 2021: $5.88BQ4 2021: $5.16BQ1 2022: $3.27BQ2 2022: $2.63BQ3 2022: $2.37BQ4 2022: $2.38BQ1 2023: $2.07BQ2 2023: $1.87BQ3 2023: $1.85BQ4 2023: $2.19BQ1 2024: $2.37BQ2 2024: $2.45BQ3 2024: $2.79BQ4 2024: $2.70BQ1 2025: $2.47BQ2 2025: $2.65BQ3 2025: $3.30BQ4 2025: $4.01BQ1 2026: $3.69BQ2 2026: $4.76B
Q1 2021Q2 2026
13F filings of Suvretta Capital Management, LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 202695$4.76BMANEARQTLEGNvs. Q1 2026SEC
Q1 2026May 15, 202688$3.69BARQTMANEPVLAvs. Q4 2025SEC
Q4 2025Feb 17, 202690$4.01BARQTBNTCLEGNvs. Q3 2025SEC
Q3 2025Nov 14, 202590$3.30BARQTBNTCMETAvs. Q2 2025SEC
Q2 2025Aug 14, 202595$2.65BARQTETNBLEGNvs. Q1 2025SEC
Q1 2025May 15, 202599$2.47BARQTBHVNBNTCvs. Q4 2024SEC
Q4 2024Feb 14, 202594$2.70BBHVNARQTITCIvs. Q3 2024SEC
Q3 2024Nov 14, 202496$2.79BBHVNKURAINSMvs. Q2 2024SEC
Q2 2024Aug 14, 202497$2.45BBHVNINSMKURAvs. Q1 2024SEC
Q1 2024May 15, 202499$2.37BBHVNKURAACLXvs. Q4 2023SEC
Q4 2023Feb 14, 202487$2.19BBHVNACLXRPRXvs. Q3 2023SEC
Q3 2023Nov 14, 202387$1.85BRPRXBHVNACLXvs. Q2 2023SEC
Q2 2023Aug 14, 2023100$1.87BRPRXBHVNACLXvs. Q1 2023SEC
Q1 2023May 15, 202392$2.07BRPRXHZNPKURAvs. Q4 2022SEC
Q4 2022Feb 14, 202389$2.38BUNHUNPOTISvs. Q3 2022SEC
Q3 2022Nov 14, 202272$2.37BUNHUNPLVSvs. Q2 2022SEC
Q2 2022Aug 15, 202289$2.63BRPRXUNHUNPvs. Q1 2022SEC
Q1 2022May 16, 202287$3.27BMSFTUNPAMZNvs. Q4 2021SEC
Q4 2021Feb 14, 202294$5.16BAMZNMSFTUNHvs. Q3 2021SEC
Q3 2021Nov 16, 2021Amended105$5.88BADBEAMZNUNHvs. Q2 2021SEC
Q2 2021Aug 16, 2021121$6.66BADBEAMZNUNHvs. Q1 2021SEC
Q1 2021May 17, 2021105$6.73BADBEELAMZN–SEC

13D and 13G filings

Companies where Suvretta Capital Management, LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

22 companies, largest stake first.

Companies where Suvretta Capital Management, LLC owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
BNTCBenitec Biopharma Inc.13D/A44.10%17.8M shares−5.80 ppfrom 49.90%May 7, 20219 filingsNov 10, 2025SEC
IFRXInflaRx N.V.13G/A15.60%22.9M shares+3.90 ppfrom 11.70%Mar 8, 20215 filingsAug 14, 2026SEC
MOLNMolecular Partners AG13G10.60%4.28M sharesNewMay 2, 20251 filingMay 2, 2025SEC
WHWKWhitehawk Therapeutics, Inc.13G9.99%4.73M sharesNewMar 11, 20251 filingMar 11, 2025SEC
DBVTDBV Technologies S.A.13G9.90%15.2M sharesNewApr 11, 20251 filingApr 11, 2025SEC
ZURAZura Bio Ltd13G/A9.90%9.52M shares+1.30 ppfrom 8.60%Jun 15, 20234 filingsMay 12, 2026SEC
AVBPArriVent BioPharma, Inc.13G/A9.90%3.41M shares–Dec 4, 20242 filingsAug 13, 2025SEC
KURAKura Oncology, Inc.13G/A9.70%8.58M shares+0.30 ppfrom 9.40%Dec 9, 20217 filingsAug 14, 2026SEC
MANEVeradermics, Inc13D/A8.80%3.72M shares−1.10 ppfrom 9.90%Feb 11, 20263 filingsAug 21, 2026SEC
IMTXImmatics N.V.13G/A8.30%11.2M shares−1.60 ppfrom 9.90%Feb 11, 20254 filingsFeb 13, 2026SEC
CMPXCompass Therapeutics, Inc.13G/A8.20%14.1M shares+3.00 ppfrom 5.20%Aug 13, 20252 filingsAug 21, 2025SEC
REPLReplimune Group, Inc.13G/A7.90%6.61M shares+2.80 ppfrom 5.10%May 12, 20262 filingsAug 6, 2026SEC
BHVNBiohaven Ltd.13G/A7.80%10.3M shares–Nov 2, 20224 filingsFeb 13, 2026SEC
FTHFaeth Therapeutics, Inc.13G7.80%2.02M sharesNewJun 23, 20261 filingJun 23, 2026SEC
LXEOLexeo Therapeutics, Inc.13G7.70%5.67M sharesNewApr 13, 20261 filingApr 13, 2026SEC
AURAAura Biosciences, Inc.13G/A7.60%4.70M shares+1.50 ppfrom 6.10%Apr 11, 20252 filingsAug 13, 2025SEC
PVLAPalvella Therapeutics, Inc.13G/A7.40%822.4K shares−1.20 ppfrom 8.60%Dec 20, 20242 filingsNov 13, 2025SEC
CAPRCapricor Therapeutics, Inc.13G6.60%3.42M sharesNewFeb 26, 20261 filingFeb 26, 2026SEC
ETNB89bio, Inc.13G/A5.60%8.28M shares−4.30 ppfrom 9.90%Oct 30, 20236 filingsNov 13, 2025SEC
AVLNAvalyn Pharma Inc.13D5.60%2.50M sharesNewMay 8, 20261 filingMay 8, 2026SEC
FULCFulcrum Therapeutics, Inc.13G/A5.50%3.68M shares−3.90 ppfrom 9.40%Aug 10, 20218 filingsAug 14, 2026SEC
MRNSMarinus Pharmaceuticals, Inc.13G5.50%3.02M shares+1.70 ppfrom 3.80%Aug 20, 20216 filingsFeb 11, 2025SEC

Latest filings

166 filings on file made by Suvretta Capital Management, LLC or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Suvretta Capital Management, LLC
CompanyFiled (ET)FormStakeChangeEvent dateFiling
MANEVeradermics, IncAug 21, 20266:32 PM ET13D/A8.80%3.72M shares−1.10 ppfrom 9.90%Aug 19, 2026SEC
ABEOAbeona Therapeutics Inc.Aug 14, 20264:25 PM ET13G/A0.90%500.0K shares−4.30 ppfrom 5.20%Below 5%Jun 30, 2026SEC
KURAKura Oncology, Inc.Aug 14, 20264:24 PM ET13G/A9.70%8.58M shares+0.30 ppfrom 9.40%Jun 30, 2026SEC
GLUEMonte Rosa Therapeutics, Inc.Aug 14, 20264:23 PM ET13G/A4.20%3.55M shares−1.30 ppfrom 5.50%Below 5%Jun 30, 2026SEC
FULCFulcrum Therapeutics, Inc.Aug 14, 20264:22 PM ET13G/A5.50%3.68M shares−3.90 ppfrom 9.40%Jun 30, 2026SEC
IFRXInflaRx N.V.Aug 14, 20264:21 PM ET13G/A15.60%22.9M shares+3.90 ppfrom 11.70%Jun 30, 2026SEC
REPLReplimune Group, Inc.Aug 6, 20265:48 PM ET13G/A7.90%6.61M shares+2.80 ppfrom 5.10%Jul 30, 2026SEC
FTHFaeth Therapeutics, Inc.Jun 23, 20264:35 PM ET13G7.80%2.02M sharesNewJun 15, 2026SEC
REPLReplimune Group, Inc.May 12, 20266:32 PM ET13G5.10%4.22M sharesNewMar 31, 2026SEC
ERASErasca, Inc.May 12, 20266:24 PM ET13G/A1.10%3.43M shares−4.00 ppfrom 5.10%Below 5%Mar 31, 2026SEC
ZURAZura Bio LtdMay 12, 20266:15 PM ET13G/A9.90%9.52M shares+1.30 ppfrom 8.60%Mar 31, 2026SEC
AVLNAvalyn Pharma Inc.May 8, 20266:52 PM ET13D5.60%2.50M sharesNewMay 1, 2026SEC
MANEVeradermics, IncMay 5, 20269:39 PM ET13D/A9.90%4.17M shares−2.00 ppfrom 11.90%May 1, 2026SEC
LXEOLexeo Therapeutics, Inc.Apr 13, 20265:03 PM ET13G7.70%5.67M sharesNewApr 6, 2026SEC
CAPRCapricor Therapeutics, Inc.Feb 26, 20267:10 PM ET13G6.60%3.42M sharesNewFeb 19, 2026SEC
STROSutro Biopharma, Inc.Feb 13, 20264:50 PM ET13G/A0.00%0 shares0.00 ppfrom 0.00%Below 5%Dec 31, 2025SEC
STROSutro Biopharma, Inc.Feb 13, 20264:49 PM ET13G/A0.00%0 shares−7.70 ppfrom 7.70%Below 5%Dec 31, 2025SEC
ZURAZura Bio LtdFeb 13, 20264:46 PM ET13G/A8.60%5.57M shares–Dec 31, 2025SEC
IMTXImmatics N.V.Feb 13, 20264:41 PM ET13G/A8.30%11.2M shares−1.60 ppfrom 9.90%Dec 31, 2025SEC
IFRXInflaRx N.V.Feb 13, 20264:32 PM ET13G/A11.70%7.93M shares–Dec 31, 2025SEC